Patents by Inventor Vincent J. Miles
Vincent J. Miles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7432047Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: October 4, 2006Date of Patent: October 7, 2008Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 7285383Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: August 1, 2005Date of Patent: October 23, 2007Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 7045284Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: June 14, 2004Date of Patent: May 16, 2006Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20040254140Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: June 14, 2004Publication date: December 16, 2004Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6824976Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: November 28, 2000Date of Patent: November 30, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6777179Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 27, 2002Date of Patent: August 17, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6667152Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 22, 2002Date of Patent: December 23, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6623961Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 28, 2002Date of Patent: September 23, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20030144226Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 27, 2002Publication date: July 31, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6579674Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 28, 2002Date of Patent: June 17, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020165194Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 28, 2002Publication date: November 7, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020160977Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 28, 2002Publication date: October 31, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020160976Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 22, 2002Publication date: October 31, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6410715Abstract: Method for screening for a non-hormone agent potentially useful to treat a hormone disorder The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.Type: GrantFiled: June 14, 2000Date of Patent: June 25, 2002Assignees: Questcor Pharmaceuticals, Inc., Mc Gill UniversityInventors: Nahum Sonenberg, Arnim Pause, Joe B. Harford, Vincent J. Miles
-
Patent number: 6156496Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: September 8, 1997Date of Patent: December 5, 2000Assignee: Ribogene, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6111077Abstract: Method for screening for a non-hormone agent potentially useful to treat a hormone disorder The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.Type: GrantFiled: February 23, 1999Date of Patent: August 29, 2000Assignees: RiboGene, Inc., McGill UniversityInventors: Nahum Sonenberg, Arnim Pause, Joe B. Harford, Vincent J. Miles
-
Patent number: 5874231Abstract: Method for screening for a non-hormone agent potentially useful to treat a hormone disorder. The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.Type: GrantFiled: August 22, 1994Date of Patent: February 23, 1999Assignees: McGill University, Ribogene, Inc.Inventors: Nahum Sonenberg, Arnim Pause, Joe B. Harford, Vincent J. Miles
-
Patent number: 5738985Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: April 1, 1994Date of Patent: April 14, 1998Assignee: Ribogene, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze